Medicare GLP-1 Bridge Pricing Guide 2026: $50/mo Copay for Eligible Seniors
Medicare GLP-1 Bridge launches July 1, 2026: $50/mo copay, ~$245/mo Medicare price, BMI 30+ comorbidity or 27+ pre-DM/CVD. Through Dec 31, 2027.
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy, Zepbound, and potentially Foundayo for $50/mo through the Medicare GLP-1 Bridge program. The bridge program runs through December 31, 2027 and provides the first concrete government-payer coverage structure for GLP-1 obesity drugs since the 2003 Medicare Modernization Act excluded weight-loss-only prescriptions from Part D coverage.
A 70-year-old without diabetes who currently pays $1,300+/mo for non-diabetes Wegovy out of pocket will, beginning July 1, see that cost compressed to $50/mo if they meet eligibility criteria. That's roughly a 96% patient-cost reduction — meaningful enough to materially change prescribing patterns in primary care for the over-65 cohort.
The program is narrower than the BALANCE pilot that was cancelled April 22, 2026. BALANCE would have created a broader pathway for obesity-only Medicare coverage; the Bridge is a more limited demonstration with specific eligibility criteria, a 2-year sunset, and a defined set of covered drugs. This guide breaks down what the program covers, who qualifies, what it costs, and what the open questions are headed into July 1.
For full GLP-1 pricing context including non-Medicare channels, see GLP-1 Pricing: May 2026. For the canceled BALANCE pilot context, see April 22 digest coverage.
Patient cost and copay structure
Eligible Part D beneficiaries pay $50/month for covered GLP-1 prescriptions through the Bridge program — a fixed copay regardless of which GLP-1 they're prescribed within the covered list. The Medicare-negotiated price under the Most-Favored-Nation (MFN) agreement runs ~$245/month, which is the share Medicare reimburses Lilly and Novo Nordisk after the patient copay.
| Channel | Price | Source |
|---|---|---|
| Patient Copay (Bridge Program) | $50/mo | SavingAdvice |
| Medicare Negotiated Price | ~$245/mo | KFF |
| Comparison: Current Wegovy Self-Pay | $499/mo | Novo Nordisk PR |
| Comparison: Wegovy WAC List Price | $1,349/mo | NovoCare |
Eligibility — BMI thresholds and comorbidity requirements
The Bridge is restricted to Part D beneficiaries who meet specific obesity-disease criteria. Weight-only prescriptions remain excluded. Patients qualify on two tracks: a BMI 30+ track with one comorbidity, or a BMI 27+ track with established pre-diabetes or cardiovascular disease. The April 22 BALANCE cancellation removed the broader pathway that would have covered weight loss as a standalone indication.
Covered drugs
The Bridge covers a defined list of FDA-approved GLP-1 medications. Wegovy (semaglutide injection 2.4 mg) and Zepbound (tirzepatide injection) are confirmed covered. Foundayo (orforglipron) coverage is anticipated but final inclusion language is pending from CMS. Wegovy pill (oral semaglutide 25 mg) inclusion is also expected. Compounded versions are not eligible.
| Channel | Price | Source |
|---|---|---|
| Wegovy (Semaglutide 2.4 mg Injection) | Covered | CMS |
| Zepbound (Tirzepatide Injection) | Covered | Eli Lilly IR |
| Foundayo (Orforglipron, Oral) | Anticipated covered | Eli Lilly PR |
| Wegovy Pill (Oral Semaglutide 25 mg) | Anticipated covered | KFF |
| Compounded Semaglutide/Tirzepatide | Not eligible | Foley & Lardner |
State Medicaid participation
State Medicaid agencies began joining the Bridge program May 1, 2026 and can opt in through January 1, 2027. Once a state joins, eligible Medicaid beneficiaries access GLP-1s under the same MFN pricing terms with state-determined cost-sharing. As of early May 2026 the participating-state list was still small; large states' decisions are pending.
Program sunset and what happens January 2028
The Bridge is a demonstration program with a defined December 31, 2027 end date. Without legislative or regulatory action before then, eligible Medicare patients on the program will face a cliff: either continued coverage under whatever permanent program replaces the Bridge, or a return to the pre-2026 status quo where weight-loss-only prescriptions are excluded from Part D. The advocacy push for permanent coverage is ongoing but unresolved.
How to enroll — the open questions
CMS hasn't yet released the operational details on how eligible patients enroll, how providers verify eligibility, and how cost-sharing is processed at the pharmacy counter. The agency has indicated that the enrollment process will use existing Part D infrastructure, with eligibility verified through prescriber attestation of BMI plus comorbidity. Final guidance is expected before the July 1 launch.